

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier Trade name	:	Ribavirin Solid Formulation		
1.2 Relevant identified uses of the substance or mixture and uses advised against					
	Use of the Sub- stance/Mixture	:	Pharmaceutical		
	Recommended restrictions on use	:	Not applicable		
1.3	Details of the supplier of the	safe	ety data sheet		
	Company	:	MSD Kilsheelan Clonmel Tipperary, IE		
	Telephone	:	353-51-601000		
	E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com		

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Germ cell mutagenicity, Category 2 Reproductive toxicity, Category 1B

Specific target organ toxicity - single exposure, Category 3 Specific target organ toxicity - repeated exposure, Category 1

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

5

Hazard pictograms



H341: Suspected of causing genetic defects.

H372: Causes damage to organs through pro-

H335: May cause respiratory irritation.

longed or repeated exposure.

of damaging fertility.

H360Df: May damage the unborn child. Suspected

Signal word

1/19

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ribavirin Solid Formulation

Version 3.3	Revision Date: 28.09.2024	SDS Number: 413005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015
Hazar	d statements	H341 Suspect H360Df May dan fertility.	use respiratory irritation. ted of causing genetic defects. mage the unborn child. Suspected of damaging damage to organs through prolonged or re- e.
Preca	utionary statements	P260 Do not b P264 Wash sl	special instructions before use. preathe dust. kin thoroughly after handling. rotective gloves/ protective clothing/ eye protec- stion.
		Response: P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/ doctor if you feel unwell. P308 + P313 IF exposed or concerned: Get medical advice/ attention.	

Hazardous components which must be listed on the label: Ribavirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Index-No. Registration number	Chemical name		Classification	Concentration (% w/w)
----------------------------------	---------------	--	----------------	--------------------------



Ribavirin Solid Formulation

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
3.3		413005-00023	Date of first issue: 11.12.2015
Ribav	irin	36791-04-5	Acute Tox. 4; H302 >= 50 - < 70 Muta. 2; H341 Repr. 1B; H360Df STOT SE 3; H335 STOT RE 1; H372 (Blood)

For explanation of abbreviations see section 16.

SECTION 4	: First aid	measures
------------------	-------------	----------

4.1 Description of first aid measure	S
General advice :	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Protection of first-aiders :	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled :	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact :	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact :	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed :	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
4.2 Most important symptoms and e	effects, both acute and delayed
Risks :	May cause respiratory irritation. Suspected of causing genetic defects. May damage the unborn child. Suspected of damaging fertili- ty. Causes damage to organs through prolonged or repeated exposure.
	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.



Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

	Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
	Unsuitable extinguishing media	:	None known.
5.2	Special hazards arising from	the	e substance or mixture
	Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
	Hazardous combustion prod- ucts	:	Carbon oxides Metal oxides
5.3	Advice for firefighters		
	Special protective equipment for firefighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
	Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
		tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions	:	Avoid release to the environment.
		Prevent further leakage or spillage if safe to do so.
		Retain and dispose of contaminated wash water.
		Local authorities should be advised if significant spillages
		cannot be contained.

Commission Regulation (EU) 2020/878

ended by



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

6.3 Methods and material for containment and cleaning up

		•••
Methods for cleaning up	:	Surround spill with absorbents and place a damp covering over the area to minimise entry of the material into the air. Add excess liquid to allow the material to enter into solution. Soak up with inert absorbent material. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfac- es, as these may form an explosive mixture if they are re- leased into the atmosphere in sufficient concentration. Clean up remaining materials from spill with suitable absor- bent. Local or national regulations may apply to releases and dis- posal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter- mine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

 i locadiono lor caro nanaling	,	
Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding
		and bonding, or inert atmospheres.
Local/Total ventilation	:	If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	:	Do not get on skin or clothing.
5		Do not breathe dust.
		Do not swallow.
		Avoid contact with eyes.
		Wash skin thoroughly after handling.
		Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure as-
		Keep container tightly closed.
		Already sensitised individuals, and those susceptible
		to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respira- tory irritants or sensitisers.
		Minimize dust generation and accumulation.
		Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.
		Take care to prevent spills, waste and minimize release to the environment.



Commission Regulation (EU) 2020/878

Ribavirin Solid Formulation

Version 3.3	Revision Date: 28.09.2024		Number: 05-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015		
Hygiene measures		flu pl na Tl er ar in	 If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 			
7.2 Condi	tions for safe storage,	includ	luding any incompatibilities			
Requirements for storage areas and containers		tię	Keep in properly labelled containers. Store locked up. Keep tightly closed. Keep in a cool, well-ventilated place. Store in accordance with the particular national regulations.			
Advic	e on common storage	S S O E	trong oxidizing	stances and mixtures		
7.3 Specif	ic end use(s)					
-	fic use(s)	: N	o data available)		

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Dust

5 mg/m3 Value type (Form of exposure): TWA (respirable dust) Basis: FOR-2011-12-06-1358

10 mg/m3 Value type (Form of exposure): TWA (total dust) Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Ribavirin	36791-04-5	Wipe limit	400 µg/100 cm²	Internal
		TWA	40 µg/m3 (OEB 3)	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

i oroonar procoorro oquipino		
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to NS EN 143 Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, han- dling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ribavirin Solid Formulation

Ver 3.3	sion	Revision Date: 28.09.2024		S Number: 3005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015
		explosion limit / Lower bility limit	:	No data available	9
	Flash p	point	:	No data available	9
	Auto-ig	nition temperature	:	No data available	9
	Decom	position temperature	:	No data available	9
	рН		:	No data available	9
	Viscosi Visc	ty cosity, kinematic	:	Not applicable	
	Solubili Wat	ty(ies) er solubility	:	No data available	9
	Partitio octanol	n coefficient: n- /water	:	Not applicable	
	Vapour	pressure	:	Not applicable	
	Relativ	e density	:	No data available	9
	Density	,	:	No data available	9
	Relativ	e vapour density	:	Not applicable	
		e characteristics icle size	:	No data available	9
9.2	Other ir	formation			
	Explosi	ves	:	Not explosive	
	Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Evapor	ation rate	:	Not applicable	

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions

tions : May form explosive dust-air mixture during processing, han-



Ribavirin Solid Formulation

Version 3.3	Revision Date: 28.09.2024		S Number: 3005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015			
			dling or other m Can react with	eans. strong oxidizing agents.			
	litions to avoid itions to avoid	:	Heat, flames ar Avoid dust form	•			
10.5 Incompatible materials Materials to avoid : Oxidizing agents							
	rdous decomposition parameters azardous decomposition						
SECTION	111: Toxicological in	for	mation				
11.1 Infor	mation on hazard class	ses	as defined in Re	gulation (EC) No 1272/2008			
Inforn expos	nation on likely routes of sure	:	Inhalation Skin contact Ingestion Eye contact				
	e toxicity lassified based on availa	ble	information.				
Produ Acute	u ct: oral toxicity	:	Acute toxicity es Method: Calcula	timate: > 2.000 mg/kg tion method			
<u>Com</u>	oonents:						
Ribay							
Acute	oral toxicity	:	LD50 (Rat): 4.11	16 - 5.584 mg/kg			
			LD50 (Mouse): >	> 10.000 mg/kg			
			LD50 (Dog): >=	1.500 mg/kg			
Acute	inhalation toxicity	:	Remarks: No da	ta available			
Acute	e dermal toxicity	:	Remarks: No da	ta available			
	toxicity (other routes of histration)	:		54 - 1.758 mg/kg te: Intraperitoneal			
			LD50 (Mouse): Application Rout	1.268 mg/kg te: Intraperitoneal			

Skin corrosion/irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Vers 3.3	sion	Revision Date: 28.09.2024		9S Number: 3005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015				
	Compo	onents:							
	Ribavi ı Remarl		:	No data available May irritate skin.					
	Serious eye damage/eye irritation Not classified based on available information.								
	Compo	onents:							
	Ribavi ı Remarl		:	No data available May irritate eyes.					
	Respir	atory or skin sensitis	atio	n					
	••••••	ensitisation ssified based on availa	ıble	information.					
	Respiratory sensitisation Not classified based on available information.								
	Compo	onents:							
	Ribavi ı Remarl		:	No data available					
		cell mutagenicity sted of causing genetic	def	ects.					
	Compo	onents:							
	Ribavi i Genoto	r in: xicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)				
				Test Type: In vitro Test system: Rode Result: positive	mammalian cell gene mutation test ent cell line				
				Test Type: Chrom Test system: Hum Result: negative	osomal aberration an lymphocytes				
	Genoto	xicity in vivo	:	Test Type: domina Species: Rat Result: negative	ant lethal test				
				Test Type: Mouse Species: Mouse Result: positive	Lymphoma				

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 3.3	Revision Date: 28.09.2024		OS Number: 3005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015
			Test Type: Micro Species: Mouse Result: positive	nucleus test
Germ sessr	cell mutagenicity- As- nent	:	Positive result(s) genicity tests.	from in vivo mammalian somatic cell muta-
	nogenicity lassified based on avail	able	information.	
<u>Com</u>	ponents:			
Expos LOAE Resu Targe Rema Speci Applio Expos NOAI Resu Rema	es cation Route sure time EL It organs arks es cation Route sure time EL It arks		mans. Rat Oral 2 Years 10 mg/kg body w negative	or mode of action may not be relevant in hu-
	sure time It	:	18 Months negative The mechanism of mans.	or mode of action may not be relevant in hu-
Mayo	oductive toxicity damage the unborn chile conents:	d. Sı	uspected of damag	ing fertility.
Ribav Effect	virin: ts on fertility	:		le e: Intraperitoneal injection < 20 mg/kg body weight ced fertility

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Version 3.3	Revision Date: 28.09.2024	SDS Number: 413005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015
		Application Ro Fertility: LOAE Symptoms: Re Result: positiv	E: 35 mg/kg body weight Educed fertility
			females
			male
Effec ment	ts on foetal develop-	Symptoms: Re fetuses, Skele	female oute: Oral Il Toxicity: LOAEL: <= 1 mg/kg body weight educed body weight, Reduced number of viable tal malformations otoxic effects and adverse effects on the off-
		Developmenta Symptoms: Re	bit, female bute: Oral ity Maternal: LOAEL: 1 mg/kg body weight Il Toxicity: LOAEL: 1 mg/kg body weight educed body weight, Skeletal malformations otoxic effects and adverse effects on the off-
		Symptoms: Sk / resorption rat	ster pute: Oral Il Toxicity: LOAEL: 2,5 mg/kg body weight keletal and visceral variations, Total Resorptions te otoxic effects and adverse effects on the off-
		Species: Rat Application Ro General Toxic Embryo-foetal	ity Maternal: NOAEL: 0,3 mg/kg body weight toxicity: LOAEL: 1 mg/kg body weight celetal malformations
Repro	oductive toxicity - As-	: Some evidenc	e of adverse effects on sexual function and



sion	Revision Date: 28.09.2024		Number: 05-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015
sessment				on animal experiments., Clear evidence of ad on development, based on animal experiments
STOT	- single exposure			
May c	ause respiratory irrit	ation.		
<u>Comp</u>	oonents:			
Ribav	virin:			
Asses	sment	: N	lay cause res	spiratory irritation.
	- repeated exposu		prolonged or	repeated exposure.
Comp	oonents:			
Ribav	virin:			
	sure routes		ngestion	
	t Organs ssment		lood	as to organs through prolonged or reported
Asses	SINCIL		auses dama xposure.	ge to organs through prolonged or repeated
			•	
Repe	ated dose toxicity		•	
-	ated dose toxicity ponents:			
-	oonents:			
Comp Ribav Speci	oonents: virin: es	: N	lonkey	
Comp Ribav Speci LOAE	oonents: virin: es L	: M : 3	1onkey 0 mg/kg	
Comp Ribav Speci LOAE Expos	oonents: virin: es	: N : 3 : 1	1onkey 0 mg/kg 0 d	intestinal tract
Comp Ribav Speci LOAE Expos Targe	oonents: ririn: es :L sure time t Organs	: M : 3 : 1 : B	lonkey 0 mg/kg 0 d llood, Gastro	intestinal tract
Comp Ribav Speci LOAE Expos	oonents: ririn: es :L sure time t Organs es	: M : 3 : 1 : B : R	lonkey 0 mg/kg 0 d lood, Gastroi	intestinal tract
Comr Ribay Speci LOAE Expos Targe Speci NOAE Applic	oonents: virin: es L sure time t Organs es EL cation Route	: M : 3 : 1 : B : R : 7 : Ir	Ionkey 0 mg/kg 0 d Ilood, Gastroi Rat ,6 mg/kg nhalation	intestinal tract
Comp Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos	ponents: virin: es L sure time t Organs es EL cation Route sure time	: M : 3 : 1 : B : R : 7 : Ir : 9	Ionkey 0 mg/kg 0 d Ilood, Gastroi tat ,6 mg/kg nhalation 0 d	intestinal tract
Comp Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos	oonents: virin: es L sure time t Organs es EL cation Route	: M : 3 : 1 : B : R : 7 : Ir : 9	Ionkey 0 mg/kg 0 d Ilood, Gastroi Rat ,6 mg/kg nhalation	intestinal tract
Comp Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe Speci	ponents: ririn: es L sure time t Organs es EL cation Route sure time t Organs es	: M : 3 : 1 : B : 7 : Ir : 9 : B : D	fonkey 0 mg/kg 0 d flood, Gastroi at ,6 mg/kg halation 0 d flood, Lungs	intestinal tract
Comp Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe Speci NOAE	ponents: ririn: es L sure time t Organs es EL cation Route sure time t Organs es	: M : 3 : 1 : B : R : 7 : Ir : 9 : B : D : 5	Ionkey 0 mg/kg 0 d Blood, Gastro at ,6 mg/kg halation 0 d Blood, Lungs	intestinal tract
Comp Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe Speci NOAE	ponents: ririn: es L sure time t Organs es EL cation Route sure time t Organs es	: M : 3 : 1 : B : 7 : Ir : 9 : B : 5 : 0 : 1	fonkey 0 mg/kg 0 d Blood, Gastroi at ,6 mg/kg halation 0 d Blood, Lungs Dog mg/kg Dral yr	
Comr Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe	ponents: ririn: es :L sure time t Organs es EL sation Route sure time t Organs es EL sation Route	: M : 3 : 1 : B : 7 : Ir : 9 : B : 5 : 0 : 1	fonkey 0 mg/kg 0 d Blood, Gastroi at ,6 mg/kg halation 0 d Blood, Lungs Dog mg/kg Dral yr	intestinal tract
Comr Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe	ponents: ririn: es :L sure time t Organs es :L cation Route sure time t Organs es :L cation Route sure time t Organs	: M : 3 : 1 : B : 7 : 1 : 7 : 1 : 9 : B : 5 : 0 : 1 : B	fonkey 0 mg/kg 0 d Blood, Gastroi at ,6 mg/kg halation 0 d Blood, Lungs Dog mg/kg Dral yr	
Comr Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe Speci NOAE Applic Expos Targe	ponents: ririn: es L sure time t Organs es EL cation Route sure time t Organs es EL cation Route sure time t Organs es EL cation Route sure time t Organs	: M : 3 : 1 : B : 7 : Ir : 9 : B : 5 : 1 : B : 5 : 1 : B : 1 : 2	fonkey 0 mg/kg 0 d lood, Gastroi at ,6 mg/kg halation 0 d lood, Lungs og mg/kg oral yr lood, Gastroi fouse 0 mg/kg	
Comr Ribav Speci LOAE Expos Targe Speci NOAE Applic Expos Targe Speci NOAE Applic Expos Targe Speci NOAE Applic Expos Targe	ponents: ririn: es L sure time t Organs es L cation Route sure time t Organs es L cation Route sure time t Organs es L cation Route sure time t Organs	: M : 3 : 1 : B : 7 : 9 : 0 : 5 : 1 : B : 5 : 1 : 1 : 1 : 9 : 1 : 5 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1 : 1	fonkey 0 mg/kg 0 d lood, Gastroi at ,6 mg/kg halation 0 d lood, Lungs og mg/kg oral yr lood, Gastroi fouse	

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ribavirin Solid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Ribavirin:	
Inhalation	: Symptoms: Headache, Dizziness
	Remarks: Based on Human Evidence
Skin contact	: Remarks: May cause eye irritation.
	Based on Human Evidence
Eye contact	: Remarks: May cause eye irritation.
	Based on Human Evidence
Ingestion	: Symptoms: blood effects, immune system effects, anorexia,
5	Dizziness, insomnia, Fatigue, Headache, Itching, Rash, liver
	function change, Gastrointestinal disturbance

SECTION 12: Ecological information

12.1 Toxicity

Components:

Riha	virin:	
Niba	VII III.	

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): > 119 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): > 117 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): > 119 mg/l Exposure time: 96 h Method: OECD Test Guideline 201 NOEC (Pseudokirchneriella subcapitata (green algae)): 6,9 mg/l Exposure time: 96 h Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Ribavirin Solid Formulation

Version 3.3	Revision Date: 28.09.2024	SDS Numb 413005-000	
Toxicity to microorganisms		Exposu Test Ty	> 1.000 mg/l re time: 3 h pe: Respiration inhibition : OECD Test Guideline 209
No da	stence and degradabi ata available ccumulative potential	lity	
	-		
Com	oonents:		
	/irin: ion coefficient: n- ol/water	: log Pow	<i>r</i> : 0,971
12.4 Mobi No da	lity in soil ata available		
12.5 Resu	lts of PBT and vPvB a	ssessment	
Prod	uct:		
Asse	ssment	to be eit	bstance/mixture contains no components considered ther persistent, bioaccumulative and toxic (PBT), or rsistent and very bioaccumulative (vPvB) at levels of higher.
12.6 Endo	ocrine disrupting prop	erties	
Prod	uct:		
Asse	ssment	ered to REACH (EU) 20	ostance/mixture does not contain components consid- have endocrine disrupting properties according to I Article 57(f) or Commission Delegated regulation 17/2100 or Commission Regulation (EU) 2018/605 at f 0.1% or higher.
12.7 Othe	r adverse effects		
No da	ata available		

SECTION 13: Disposal considerations

13.1 Waste treatment methods Product Dispose of in accordance with local regulations. : According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. Contaminated packaging Empty containers should be taken to an approved waste han-: dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.



Commission Regulation (EU) 2020/878

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

SECTION 14: Transport information

14.1 UN number or ID number

	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.2	2 UN proper shipping name		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.3	3 Transport hazard class(es)		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	ΙΑΤΑ	:	Not regulated as a dangerous good
14.4	4 Packing group		
	ADN	:	Not regulated as a dangerous good
	ADR	:	Not regulated as a dangerous good
	RID	:	Not regulated as a dangerous good
	IMDG	:	Not regulated as a dangerous good
	IATA (Cargo)	:	Not regulated as a dangerous good
	IATA (Passenger)	:	Not regulated as a dangerous good
14.	5 Environmental hazards		
	Not regulated as a dangerous	aor	bd

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks	:	Not applicable for product as supplied.
---------	---	---



Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
3.3	28.09.2024	413005-00023	Date of first issue: 11.12.2015

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EC) on substances that deplete the ozone laver	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable
Regulation (ÉU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliar	nen	t and of the Council o

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version	
		are highlighted in the body of this document by two vertical	
		lines.	

Full text of H-Statements

H302 :	Harmful if swallowed.	
H335 :	May cause respiratory irritation.	
H341 :	Suspected of causing genetic defects.	
H360Df :	May damage the unborn child. Suspected of damaging fertili-	



Ribavirin Solid Formulation

Version 3.3	Revision Date: 28.09.2024	SDS Number: 413005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015	
H372		ty. : Causes dama exposure if sw	ge to organs through prolonged or repeated /allowed.	
Full te	ext of other abbreviat	ions		
-	RE	 Reproductive Specific targe Specific targe Norway. Occu 	Acute toxicity Germ cell mutagenicity Reproductive toxicity Specific target organ toxicity - repeated exposure Specific target organ toxicity - single exposure Norway. Occupational Exposure limits Long term exposure limit	

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

: Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/



Version 3.3	Revision Date: 28.09.2024	SDS Number: 413005-00023	Date of last issue: 06.04.2024 Date of first issue: 11.12.2015
Classification of the mixture:			Classification procedure:
Muta.	2	H341	Calculation method
Repr.	1B	H360Df	Calculation method
STOT	SE 3	H335	Calculation method
STOT	RE 1	H372	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN